Lucid Diagnostics Inc. (LUCD) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Lucid Diagnostics Inc. (LUCD) closed at USD 0.54 on 2026-10-14, a change of -57.2 % over the past year, with a market capitalization of USD 99.31M.

Lucid Diagnostics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Lucid Diagnostics Inc. key figures

Previous close

USD 0.54 (2026-10-14)

1-year change

-57.2 %

Market cap

USD 99.31M

Enterprise value

USD 89.75M

P/E ratio (trailing)

-1.33

P/E ratio (forward)

-3.15

EPS (trailing)

-0.39

EPS (forward)

-0.17

PEG ratio

n/a

Price to book

9.12

Revenue growth

26.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.71

Employees

82

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Lucid Diagnostics Inc. and compare it with other stocks.